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Objective: We studied the hemostatic effects of tranexamic acid in patients under-
going elective surgery involving the thoracic aorta.
Methods: In a double-blind, randomized fashion, 60 consecutive patients were
assigned to two treatment groups: 30 patients (placebo group) received infusion of
saline solution, and 30 (treatment group) received tranexamic acid (1 g before skin
incision, an infusion of 400 mg/h during the operation, and 500 mg in the pump
priming). Perioperative bleeding was considered as a primary outcome. Periopera-
tive allogeneic transfusions, major thrombotic complications (myocardial infarction,
pulmonary embolism, renal insufficiency), and surgical outcomes were also con-
sidered.
Results: Patients treated with tranexamic acid showed significant reductions in
postoperative bleeding, both in terms of the amount collected during the first 4
postoperative hours (median 307 mL, interquartile range 253–361 mL in the placebo
group vs median 211 mL, interquartile range 108–252 mL in the treatment group,
P  .002) and in terms of total bleeding (median 722 mL, interquartile range
574–952 mL in the placebo group vs median 411 mL, interquartile range 313–804
mL in the treatment group, P  .04). Consequently, the number of patients
transfused differed significantly between groups (21 patients [72.4%] in the placebo
group vs 13 [44.8%] in the treatment group, P  .033). Patients in the treatment
group showed significant reductions in the total amount for the entire group of
packed red cells transfused (13,500 mL in the treatment group vs 28,000 mL in the
placebo group, P  .012) and in the total amount of allogeneic transfusions (23,400
mL in the treatment group vs 53,000 mL in the placebo group, P  .024). No
differences in perioperative thrombotic complications were found.
Conclusions: In this initial series of patients undergoing thoracic aortic surgery,
tranexamic acid appeared effective in reducing perioperative bleeding, with a
significant reduction in the need for allogeneic transfusions and without any in-
creased risk of thrombotic complications.
Excessive perioperative bleeding and the consequent increased needfor allogeneic transfusions frequently complicate the outcome ofpatients undergoing thoracic aortic surgery. This bleeding is due toextended surgical dissection, the fragile tissues of the diseased aorta,and changes in coagulation processes related to cardiopulmonarybypass (CPB) and deep hypothermia and circulatory arrest
(DHCA).1,2 The use of drugs with hemostatic properties has been widely addressed
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as a strategy to reduce perioperative bleeding in cardiac
operations.3 Previously published studies have systemati-
cally evaluated in patients undergoing thoracic aortic sur-
gery the hemostatic effects of aprotinin, a nonspecific serine
protease inhibitor with antifibrinolytic properties. There is a
lack, however, of prospective, placebo-controlled studies
involving such drugs as -aminocaproic acid and tranex-
amic acid, two synthetic antifibrinolytic drugs with demon-
strated efficacy in reducing perioperative bleeding and al-
logeneic transfusions in cardiac surgery.4
In our institution, as a consequence of previously pub-
lished studies, we routinely administer tranexamic acid to
patients undergoing cardiac operations.5,6 The aim of this
study was to evaluate the effects of tranexamic acid on
perioperative bleeding and allogeneic transfusions also in
patients submitted to elective thoracic aortic surgery.
Methods
After institutional review board approval was obtained, along with
informed consent from each patient, from January 1, 2000, to May
31, 2001, a total of 60 consecutive patients scheduled in our
institution for elective thoracic aortic surgery were enrolled in the
study. Exclusion criteria were as follows: advanced chronic renal
insufficiency (creatinine 2 mg/dL), active chronic hepatitis or
cirrhosis, and history of hematologic disorders. On the basis of
these criteria, 1 patient was not included in the study (chronic renal
insufficiency with preoperative creatinine of 3.5 mg/dL). Preoper-
ative treatment with aspirin or anticoagulant was not a contrain-
dication to the enrollment in the trial.
A standardized protocol for anesthesia was applied. Premedi-
cation was obtained with intramuscularly administered morphine
(0.1 mg/kg) and scopolamine (0.5 mg). Induction and maintenance
of anesthesia were performed with propofol, midazolam, and fen-
tanyl, with nitrous oxide and isoflurane as needed. Muscle relax-
ation was obtained with pancuronium bromide.
Surgical Protocol
Tables 1 and 2 summarize the aortic pathologic conditions and the
interventions performed in the two groups of patients. All the
patients were operated on through a full median sternotomy, with
the exception of 2 patients with descending thoracic aortic aneu-
rysm, 1 per group, who underwent the only replacement of the
descending thoracic aorta through a left thoracotomy performed in
the fourth intercostal space. Most patients had disease of the aortic
root, and a combined operation on the aortic valve and ascending
aorta was performed. A total of 6 patients (3 patients per group)
required DHCA, 5 because of surgery involving the aortic arch and
1 because of surgery on a calcified ascending aorta. Before arterial
cannulation (aorta or femoral artery), full heparinization was ob-
tained (3 mg/kg), and additional heparin was administered to
maintain a celite activated coagulation time 480 seconds or higher
(Actalyke; Helena Laboratories, Beaumont, Tex). The circuit for
extracorporeal circulation comprised a roller pump (SC Stockert;
Stockert Instrumente GmbH, Mu¨nchen, Germany), which guaran-
teed a nonpulsatile blood flow, and a hollow-fiber membrane
oxygenator (Affinity; Dideco, Mirandola, Italy). Priming of the
circuit consisted of 1700 mL of a balanced crystalloid and colloid
solution (1300 mL Ringer lactate, 250 mL 18% mannitol, and 150
mL plasma expander). Myocardial protection during aortic cross-
clamping was achieved with cold blood cardioplegia. DHCA was
achieved with standardized methods, and in these cases cerebral
protection was performed through retrograde cerebral perfusion.
At the end of CPB, heparin was antagonized with protamine
sulfate (1:1 ratio); if needed, additional protamine was adminis-
tered in 50-mg incremental doses to obtain an activated coagula-
tion time value equal to or shorter than the baseline. A cell-saver
circuit (Compact Advanced; Dideco) was used to recoup blood
from the operative field and to process the blood remaining in the
extracorporeal circuit after the cessation of CPB.
Pharmacologic Protocol and Sampling Times
The 60 patients were prospectively randomized, in a double-
blinded fashion, into two groups: a placebo control group (30
patients), who received an infusion of saline solution, and a treat-
ment group (30 patients), who received tranexamic acid (bolus of
1 g in 20 minutes after induction of anesthesia but before skin
incision, and continuous infusion of 400 mg/h during the whole
surgical time. An additional 500 mg of the drug was added to the
priming of CPB. The staffs of both the operating room and the
intensive care unit were blinded to the treatment. The correct
procedure was ensured by means of coded infusion syringes pre-
pared by the pharmacy of our center.
Samples for evaluation of hemoglobin, hematocrit, platelet
count, fibrinogen, prothrombin time, activated partial thrombo-
plastin time, creatinine, creatine kinase, and creatine kinase MB
isoenzyme were taken before the induction of anesthesia (time 1),
on the patient’s arrival in the intensive care unit (time 2), at 24 and
48 hours after the operation (times 3 and 4), and at discharge
(time 5).
Criteria for Allogeneic Transfusion and Surgical
Reexploration
A standardized intraoperative and postoperative protocol for trans-
fusion of allogeneic products was applied. During CPB, packed
TABLE 1. Diagnoses of thoracic aorta disease
Placebo group
(n  30)
Tranexamic
acid group
(n  30)
No. % No. %
Aneurysm (no.)
Ascending aorta 23 76.7 24 80
Ascending aorta
and aortic arch
1 3.3 2 6.7
Total 24 80 26 86.7
Dissection (no.)
Type I 1 3.3 1 3.3
Type II 4 13.3 2 6.7
Type IIIb 1 3.3 1 3.3
Total 6 20 4 13.3
Dissection types follow the DeBakey classification of aortic dissection
(Ann Surg. 1955;162:586).
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red blood cells (PRBCs) were transfused if the hemoglobin value
was less than 6.5 g/dL and the hematocrit value was less than 20%.
After CPB and during the postoperative period, PRBCs were
transfused if the hemoglobin value was less than 8 g/dL and the
hematocrit value was less than 24%. Fresh-frozen plasma (FFP)
was infused after protamine administration if prothrombin time
value was 1.5 times the baseline and there was microvascular
bleeding. Platelet concentrate (PLTC) was transfused in the pres-
ence of microvascular bleeding and a platelet count less than
50,000 cells/mm3. The total amount of allogeneic blood products
transfused in each group was calculated as the sum of the single
units: 1 bag of PRBCs was 300 mL, 1 bag of FFP was 500 mL, and
one unit of PLTC was 50 mL.
Blood loss was recorded during the first 24 hours. We defined
excessive bleeding as a total amount greater than 600 mL/24 h.
Chest drains were removed when bleeding was less than 100 mL
in the last 4 hours. Surgical reexploration was considered when
bleeding in the first 2 hours was greater than 300 mL/h or if it was
greater than 200 mL/h for 4 consecutive hours, with normal
coagulation data.
Postoperative Evaluation
As a possible consequence of antifibrinolytic therapy, the follow-
ing thrombotic complications were recorded during the first 24
postoperative hours: myocardial infarction (new Q waves on elec-
trocardiogram, creatine kinase MB isoenzyme to creatine kinase
ratio greater than 10%, troponin I value greater than 0.1 ng/dL),
acute renal insufficiency (creatinine value twice the baseline or
need for dialysis), major neurologic dysfunction (transient is-
chemic attack or stroke), deep venous thrombosis, and pulmonary
embolism.
Statistical Analysis
The trial was designed to detect a difference between the groups of
200 mL in postoperative bleeding with an SD of 250 mL. This
design was based on data emerging from a previous study.5 To
achieve significance, a minimum of 25 patients per group was
required, with a one-tailed  error of .05 and a power of 80%. To
test the normality of the distribution of the continuous variables,
the Kolmogorov-Smirnov test was performed. The normally dis-
tributed data at each time were compared between the groups with
a 2-tailed unpaired Student t test and expressed as mean  SD.
Nonnormally distributed variables were compared by Mann-Whit-
ney U test and expressed as median and interquartile range (25th-
75th percentiles). Categoric data were analyzed with the 2 test or
the Fisher exact test as appropriate. Two-way analysis of variance
with repeated measures on one factor was used to evaluate the
main effect of group on the hematologic variables, the effect of the
time, and the group-time interaction. Data were analyzed with the
SPSS 6.0 statistical package (SPSS Inc, Chicago, Ill).
Results
Of the 60 patients enrolled, 2 patients did not complete the
study. They were excluded from statistical analysis. These
two patients died in the operating room, both of cardiogenic
shock refractory to maximal inotropic support. One patient
in the control group, with ascending aorta aneurysm and
aortic valve insufficiency, underwent separate aortic valve
and ascending aorta substitution, and one patient in the
tranexamic acid group, with a history of coronary disease
and aneurysm of ascending aorta with aortic valve insuffi-
ciency, underwent combined intervention of coronary re-
vascularization, aortic valve reconstruction, and ascending
aorta substitution. The remaining 58 patients were consid-
ered for statistical analysis. Their demographic and preop-
erative hematologic data are shown in Tables 3 and 4. No
differences between the groups emerged. As evidenced in
Table 5, the two groups were also homogeneous with re-
TABLE 2. Surgical procedures on thoracic aorta
Placebo group
(n  30)
Tranexamic acid group
(n  30)
No. % No. %
Previous intervention on thoracic aorta 3 10 3 10
Graft replacement of ascending aorta 2 6.7 2 6.7
Bentall-DeBono technique 5 16.7 4 13.3
Cabrol technique 0 0 1 3.3
Separate replacement of aortic valve and ascending aorta 9 30 11 36.7
Aortic valve replacement and ascending aorta reconstruction 3 10 5 16.7
Aortic valve reconstruction and ascending aorta replacement 7 23.3 4 13.3
Aortic valve reconstruction and ascending aorta and aortic
arch replacement
1 3.3 1 3.3
Aortic valve, ascending aorta, and aortic arch replacement 2 6.7 1 3.3
Descending aorta replacement 1 3.3 1 3.3
DHCA 3 10 3 10
Combined procedures
Coronary artery bypass grafting 4 13.3 3 10
Coronary artery bypass grafting and mitral valve
replacement
1 3.3 2 6.7
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spect to the operative data. Table 6 summarizes postopera-
tive bleeding and perioperative allogeneic transfusions. Sig-
nificant differences were found in bleeding during the first 4
postoperative hours and in the total amount of blood loss
recorded during the first 24 postoperative hours, both of
which were significantly higher in the placebo group. The
percentage of patients who showed excessive bleeding was
significantly higher in the placebo control group (62.1% vs
34.5% in treatment group, P  .036). Consequently, the
number of patients requiring allogeneic transfusions was
also significantly higher in the placebo group (Table 6). In
particular, there were significant differences in terms of the
total amount of perioperative PRBC transfusion. The num-
ber of patients transfused with FFP and the total amount of
FFP transfused was higher in the placebo control group, but
without reaching statistical significance. No differences
were recorded in terms of PLTC transfused. All the hema-
tologic variables considered changed significantly with
time, but no significant differences were found between the
groups or as a time-group interaction (data not shown).
Finally, as evidenced in Table 7, no differences were found
in major complications during the first 24 postoperative
hours. Two patients in each group required surgical reex-
ploration for bleeding: a surgical source was found in 2
patients (1 per group). The other two patients showed dif-
fuse bleeding necessitating transfusion of FFP and PLTC.
Four patients died during the postoperative period: 2 pa-
tients in the placebo group because of low cardiac output–
related organ dysfunction, 1 patient in the tranexamic acid
group because of respiratory insufficiency, and 1 patient in
the tranexamic acid group because of multiple organ failure
after low cardiac output.
Discussion
To the best of our knowledge, this is the first study in which
the hemostatic properties of a synthetic antifibrinolytic drug
have been tested in a prospective, randomized, double-
blinded manner on patients undergoing thoracic aortic op-
erations. This type of surgery is characterized by high
incidence of perioperative bleeding, and the reasons are
complex. Preoperative reasons include the fragility of the
diseased aortic tissues and alterations in coagulation related
to excessive fibrinolysis as a consequence of the exposure of
the blood to thromboplastin within atherosclerotic plaque in
TABLE 3. Demographic characteristics
Placebo group
(n  29)
Tranexamic acid
group (n  29) P value
Age (y, mean  SD) 63 11 59 13 .21
Male sex (no.) 19 (65.5%) 23 (79.3%) .24
Height (cm, mean  SD) 168 10 168 11 .97
Weight (kg, mean  SD) 76 17 74 14 .66
Baseline left ventricular ejection fraction
(%, mean  SD)
54 11 58 9 .12
New York Heart Association functional class
(median and interquartile range)
2 (2-3) 2 (2-3) .54
Previous cardiac operation (no.) 7 (24.1%) 9 (31.0%) .56
Preoperative aspirin (no.) 5 (17.2%) 6 (20.7%) .94
Preoperative anticoagulant (no.) 6 (20.7%) 6 (20.7%) .999
The t test, Mann-Whitney U test, 2 test, or Fisher exact test was used as appropriate to determine P values.
TABLE 4. Baseline hematochemical data
Placebo group
(n  29)
Tranexamic acid
group (n  29) P value
Hemoglobin (g/dL, mean  SD) 14 1.3 14 1.6 .83
Hematocrit (%, mean  SD) 42.2 4.1 41.2 4.5 .57
Platelet count (103 cells/mm3, mean  SD) 196 41 190 51 .66
Fibrinogen (mg/dL, median and interquartile range) 394 (291-446) 374 (320-450) .68
Prothrombin time (%, median and interquartile range) 86 (70-100) 94 (78-100) .54
Activated partial thromboplastin time (s, median and
interquartile range)
34 (31-36) 35 (30-37) .75
Activated coagulation time (s, mean  SD) 151 30 146 27 .42
Creatinine (mg/dL, mean  SD) 1.0 0.3 0.9 0.2 .11
Creatine kinase (U/L, median and interquartile range) 65.5 (49-85) 73 (60.5-100) .17
The t test or Mann-Whitney U test was used as appropriate to determine P values.
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patients with aortic dissection or aneurysm rupture.7 Oper-
ative causes of bleeding include the large surgical surfaces,
the use of CPB, and DHCA.8,9
During cardiac operations performed with CPB, both the
intrinsic pathway, through the contact of the blood with the
foreign surfaces of the circuit for extracorporeal circulation,
and the extrinsic pathway, through the activation of tissue
factor, are intensively stimulated.10,11 The wide surgical
dissection areas determine activation of the extrinsic path-
way through the release of tissue factor by endothelial cells.
Hypothermia induces profound alteration of the coagulation
system through speed reduction in enzymatic activity and
alteration of platelet morphology, with decreased platelet
aggregation following the reduction of thromboxane release
and plasmin-related degradation of glycoprotein Ib recep-
tors.2,9 Circulatory arrest determines stagnation of the blood
into the vascular bed, and through the production of tissue
plasminogen activator by endothelial cells, thrombin is pro-
duced and the fibrinolytic system is induced. There is also
the activation of protein C, which exerts a potent anticoag-
ulant effect through the inhibition of factors Va and VIIIa
and the inactivation of plasminogen activator inhibitor types
I and III, thus promoting fibrinolysis.8 All these factors
contribute to the complex hemostatic alterations and the
TABLE 5. Operative data
Placebo group (n  29)
Tranexamic acid group
(n  29) P value
CPB time (min, median and interquartile range) 145 (120-170) 134 (119.5-159) .18
Aortic crossclamping time (min, median and interquartile range) 107 (92-117) 115 (94.5-133.25) .64
DHCA (min, median and range) 35 (32-45) 38 (28-43) .83
Lowest temperature during CPB (min, median and interquartile range) 31.65 (30.6-32.75) 32.9 (30-34) .25
Total heparin dose (mg, median and interquartile range) 250 (200-270) 250 (210-270) .88
Total protamine dose (mg, median and interquartile range) 250 (200-300) 250 (200-250) .28
Minimum hematocrit during CPB (%, median and interquartile range) 22.5 (19.75-26) 24 (21.5-26.5) .32
Intraoperative autotransfusion (mL, median and interquartile range) 693 (550-1116) 775 (600-1131.75) .89
The Mann-Whitney U test was used as appropriate to determine P values. Lower temperature during CPB refers to the patients operated on without DHCA.
TABLE 6. Postoperative bleeding and perioperative allogeneic transfusions
Placebo group
(n  29)
Tranexamic acid
group (n  29) P value
Bleeding
Bleeding in 1st 4 h (mL, median and interquartile range) 307 (253-361) 211 (108-252) .002
Total bleeding (mL, median and interquartile range) 722 (574-952) 411 (313-804) .04
Excessive bleeding (no.) 18 (62.1%) 10 (34.5%) .04
PRBCs in operating room
Total volume transfused (mL) 3300 1200 .22
Patients transfused (no.) 5 2
Total PRBCs
Total volume transfused (mL) 24,600 9600 .01
Patients transfused (no.) 19 11
FFP in operating room
Total volume transfused (mL) 2000 2000 .999
Patients transfused (no.) 2 2
Total FFP
Total volume transfused (mL) 28,000 13,000 .12
Patients transfused (no.) 15 9
PLTC in operating room
Total volume transfused (mL) 0 300 .32
Patients transfused (no.) 0 1
Total PLTC
Total volume transfused (mL) 400 300 .9
Patients transfused (no.) 1 1
All blood products
Total volume transfused (mL) 53,000 23,400 .02
Patients transfused (no.) 21 (72.4%) 13 (44.8%) .03
The Mann-Whitney U test, 2 test, or Fisher exact test was used as appropriate to determine P values. Excessive bleeding was considered to be more
than 600 mL in the first 24 hours.
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derived abnormal perioperative bleeding frequently seen in
patients undergoing thoracic aortic surgery.
The principal consequence of excessive perioperative
blood loss is an increased need for allogeneic transfusions,
with the derived risks of immunologic reactions and viral
infectious diseases such as hepatitis C and acquired immu-
nodeficiency syndrome.12 In addition, patients with exces-
sive bleeding are exposed to a higher rate of surgical reex-
ploration, with consequent increased risks of morbidity and
mortality.13
A study by Svensson and colleagues14 demonstrated that
patients undergoing thoracic aorta operations who did not
receive allogeneic blood transfusions had better outcomes.
Methods of reducing allogeneic transfusions, such as pre-
operative autologous blood donation, intraoperative iso-
volemic hemodilution, intraoperative blood salvage and re-
infusion, and the use of drugs with hemostatic properties,
have therefore received great attention of late.15 In particu-
lar, many previously published randomized, double-blind,
prospective trials have evaluated the hemostatic effects of
aprotinin in aortic surgery, particularly when performed
with DHCA,16-20 whereas no one has considered the syn-
thetic antifibrinolytic drugs -aminocaproic acid and tran-
examic acid. Aprotinin is a product naturally derived from
bovine lung with nonspecific antiprotease and antifibrino-
lytic properties, and it has a complex action on the coagu-
lation system.21 Even though significant reductions in peri-
operative bleeding and allogeneic transfusions have been
reported with this drug, in various reports its use in aortic
surgery with DHCA has been related to an increased risk of
thrombotic complications, such as renal insufficiency, myo-
cardial infarction, and death.20,22-24 For these reasons the use
of aprotinin continues to be debated.
Tranexamic acid and -aminocaproic acid are two low-
cost synthetic antifibrinolytic drugs that prevent the plas-
min-mediated conversion of fibrinogen to fibrinogen split
products through the inhibition of the lysine-binding sites
on plasminogen and fibrinogen, thus blocking fibrinolysis.25
They also exert a protective effect on platelets through the
inhibition of plasminogen and plasmin at platelets, thus
blocking the activation of platelets as a result of local
plasmin concentration.26 The use of -aminocaproic acid in
thoracic aortic surgery has been proposed by various au-
thors.14,15,27,28 In a retrospective study, Eaton and cowork-
ers27 compared aprotinin with -aminocaproic acid in 49
patients undergoing aortic surgery involving DHCA. They
concluded that the two drugs appeared equally efficacious in
reducing perioperative bleeding and transfusion require-
ment. Svensson and colleagues14,15 and Cohn and cowork-
ers28 proposed the administration of -aminocaproic acid
among potential strategies to reduce the bleeding associated
with thoracic aortic surgery.
Until now no study has considered tranexamic acid as an
antifibrinolytic drug in thoracic aorta surgery. In our insti-
tution, as a consequence of the results of previously pub-
lished studies, tranexamic acid is routinely administered to
all patients undergoing cardiac surgery with CPB,5,6 and
recently it has also been administered to patients undergoing
beating-heart coronary operations without extracorporeal
circulation.29 We therefore elected to evaluate the hemo-
static effects of tranexamic acid in patients undergoing
thoracic aortic surgery. Our most important result was the
TABLE 7. Outcomes and perioperative complications
Placebo group
(n  29)
Tranexamic acid
group (n  29) P value
Surgical reexploration for bleeding (no.) 2 (6.9%) 2 (6.9%) .999
Intubation time (h, median and interquartile range) 8.5 (5.5–17) 7 (5-10) .14
Hospital stay (d, median and interquartile range)
Intensive care unit stay 1 (1-2) 1 (1-2) .47
Postoperative hospital stay 8 (7-11) 7 (6-8) .19
Cardiac complications (no.)
Low cardiac output necessitating major inotropic therapy 6 (20.7%) 5 (17.2%) .74
Atrial fibrillation 5 (17.2%) 6 (20.7%) .74
Heart block requiring pacemaker implantation 2 (6.9%) 1 (3.4%) .5
Myocardial infarction 1 (3.4%) 1 (3.4%) .999
Renal failure (no.)
Creatinine double baseline 5 (17.2%) 4 (13.8%) .72
Dialysis 1 (3.4%) 1 (3.4%) .999
Neurologic complications (no.)
Minor 1 (3.4%) 2 (6.9%) .5
Stroke 2 (6.9%) 1 (3.4%) .5
Pulmonary embolism (no.) 0 (0%) 0 (0%) .999
Postoperative death (no.) 2 (6.9%) 2 (6.9%) .999
The Mann-Whitney U test, 2 test, or Fisher exact test was used as appropriate to determine P values.
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significant reduction in perioperative bleeding, and conse-
quently in the amount of allogeneic transfusions, among the
patients treated with tranexamic acid. In particular we ob-
served a reduction of about 30% in the number of patients
who required at least one type of allogeneic blood product.
The antihemorrhagic effects of the drug are clearly demon-
strated by the reduction of bleeding, particularly during the
first 4 postoperative hours when the drug is present in the
blood in therapeutic concentrations.25 In addition, the quan-
tity of FFP transfused was clearly greater in the placebo
group, although this difference did not reach statistical
significance, probably because of the relatively small num-
ber of patients enrolled.
Another important aspect of the use of antifibrinolytic
drugs is the theoretic possibility of an increased rate of
thrombotic complications. In this relatively small series of
patients we did not observe any difference between treated
and untreated patients, and the occurrences of thrombotic
complications in both groups were similar to those de-
scribed in previous published studies.30,31 One patient in the
tranexamic acid group with a history of associated coronary
disease died intraoperatively of cardiogenic shock; in this
case an autopsy was not performed, so conclusions regard-
ing a possible myocardial ischemia induced by a thrombotic
complication related to tranexamic acid are not possible.
Further studies on a greater number of patients with the
primary outcomes of morbidity and mortality may lead to
more precise answers.
One limitation of the study is the relatively small number
of patients operated on with DHCA. Because of the pro-
found alterations of coagulation seen with DHCA, this
group could benefit greatly from therapy with tranexamic
acid. This may be an interesting area for further studies.
Another limitation is that this was a clinical study, with no
specific laboratory evaluations of platelet function, coagu-
lation, and fibrinolysis. Because of this, no conclusions
regarding the functional aspect of tranexamic acid in this
type of surgery are possible. Additional studies may com-
pare tranexamic acid with the principal hemostatic drugs
currently used in cardiac surgery, such as aprotinin and
-aminocaproic acid, to examine their different biochemical
effects on coagulation and the fibrinolytic system.
Conclusions
To conclude, in this initial series of patients undergoing
operations involving the thoracic aorta, the use of tranex-
amic acid led to a significant reduction in perioperative
bleeding and consequently in the need for allogeneic trans-
fusions. Further studies with larger numbers of patients are
required to confirm these initial observations and to exclude
the theoretic risk of an increased rate of thrombotic com-
plications.
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